



Thermo Fisher Scientific Strengthens Sales Channel and Life Sciences Portfolio with the Addition of Spectronex and Flux Instruments

WALTHAM, Mass. (January 15, 2007) – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has acquired SwissAnalytic Group AG, based in Basel, Switzerland. SwissAnalytic Group owns Spectronex AG and Flux Instruments AG, which had combined revenue of approximately \$22 million USD in fiscal year 2006.

Spectronex is a leading supplier of mass spectrometry, chromatography and surface science instrumentation in Switzerland, Austria, Slovakia and the Czech Republic. As Thermo Fisher Scientific expands its field sales presence in Europe, this acquisition will bring additional direct sales, demonstration capabilities and visibility to customers in these regions.

Flux Instruments is a manufacturer of high performance liquid chromatography (HPLC) pumps and software. Flux brings new technology and design expertise to Thermo Fisher Scientific's current HPLC and LCMS business, which includes the new Thermo Scientific Accela™ UHPLC as well as advanced sample extraction and liquid chromatography products gained through the recent acquisition of Cohesive Technologies. Flux will enhance the company's product portfolio with complementary technologies and intellectual property for future product development.

"Flux Instruments is a strong complement to our expanding chromatography and life sciences mass spectrometry product lines," said Marijn E. Dekkers, president and chief executive officer of Thermo Fisher Scientific. "In addition, Spectronex enables Thermo Fisher to strengthen our footprint in Europe with direct sales channels and support, enhancing our ability to work closely with important customers in this area."

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual sales of more than \$9 billion, we employ 30,000 people and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit www.thermofisher.com.

The following constitutes a "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include those discussed in Thermo Electron and Fisher Scientific's Quarterly Reports on Form 10-Q for the third quarter of 2006 under the caption "Risk Factors," both of which are on file with the Securities and Exchange Commission



and available in the "Investors" section of our Website under the heading "SEC Filings." We also may make forward-looking statements about the benefits of the merger of Thermo Electron and Fisher Scientific, including statements about future financial and operating results, the new company's plans, objectives, expectations and intentions and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the risk that the businesses will not be integrated successfully; the risk that the cost savings and any other synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; dependence on customers' capital spending policies and government funding policies; realization of potential future savings from new productivity initiatives; dependence on customers that operate in cyclical industries; general worldwide economic conditions and related uncertainties; the effect of changes in governmental regulations; exposure to product liability claims in excess of insurance coverage; and the effect of exchange rate fluctuations on international operations. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

###